Effective Oct. 1, 2023, we’ll require prior authorization for the following colony-stimulating factor medication HCPCS code when administered in outpatient settings as treatment for cancer diagnosis:
HCPCS code | Description |
---|---|
J1449 | Injection, eflapegrastim-xnst, 0.1 mg |
These changes affect UnitedHealthcare commercial plans and UnitedHealthcare® Medicare Advantage plans in all states, as well as UnitedHealthcare Community Plan and UnitedHealthcare Individual Exchange* plans in specific states, as outlined below.
Arizona | Kentucky | Mississippi | Ohio | Texas |
Florida | Louisiana | Nebraska | Pennsylvania | Virginia |
Hawaii | Maryland | New Jersey | Rhode Island | Washington |
Kansas | Minnesota | New York | Tennessee | Wisconsin |
Alabama | Illinois | Michigan | Ohio | Texas |
Arizona | Kansas | Missouri | Oklahoma | Virginia |
Florida | Louisiana | Mississippi | Tennessee | Washington |
Georgia | Maryland | North Carolina |
You can submit a prior authorization request through the UnitedHealthcare Provider Portal:
To support our review, we’ll document clinical requirements within the request submission. You may also be asked to attach medical records.
For questions about oncology prior authorization: